Therapeutic antibody fragments with prolonged in vivo half-lives

Nature Biotechnology

Volumn 17, Issue 8, 1999, Pages 780-783

  Chapman, Andrew P ^b   Antoniw, Pari ^a   Spitali, Mariangela ^a   West, Shauna ^a   Stephens, Sue ^a   King, David J ^b  

^a UCB PHARMA   (Belgium)

^b Coulter Pharmaceutical ^*  (United States)

Author keywords

Antibody engineering; Pharmacokinetics; Polyethylene glycol; Therapeutic antibodies

Indexed keywords

ANTIBODY; MACROGOL; PEPTIDE FRAGMENT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN BINDING; AREA UNDER THE CURVE; ARTICLE; CHRONIC DISEASE; DRUG CLEARANCE; DRUG CONJUGATION; DRUG HALF LIFE; DRUG ISOLATION; DRUG RETENTION; MALE; MONKEY; NONHUMAN; PHAGE DISPLAY; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT;

ANIMALS; AREA UNDER CURVE; HALF-LIFE; IMMUNOGLOBULIN FRAGMENTS; IMMUNOTHERAPY; MACACA FASCICULARIS; MALE; POLYETHYLENE GLYCOLS; RATS; RATS, WISTAR;

ANIMALIA;

EID: 0032868653     PISSN: 10870156     EISSN: None     Source Type: Journal    
DOI: 10.1038/11717     Document Type: Article

References (16)

1. Vaughan, T.J., Osbourn, J.K. & Tempest, P.R. Human antibodies by design. Nat. Biotechnol. 16, 535-539 (1998).
2. Dickman, S. Antibodies stage a comeback in cancer treatment. Science 280, 1196-1197 (1998).
3. Elliott, M.J. et al. Randomised double-blind comparison of chimeric monoclonal antibody to tumor necrosis factor α (cA2) versus placebo in rheumatoid arthritis. Lancer 344, 1105-1110 (1994).
4. Rankin, E.C.C. et al. The therapeutic effects of an engineered human anti-tumour necrosis factor alpha antibody (CDP571) in rheumatoid arthritis. Br. J. Rheumatol. 34, 334-342 (1995).
5. Bebbington, C.R. et al. High-level expression of a recombinant antibody from myeloma cells using a glutamine synthetase gene as an amplifiable marker. Bio/Technology. 10, 169-175 (1992).
6. Skerra, A. & Pluckthun, A. Assembly of a functional immunoglobulin Fv fragment in Escherichia coli. Science 240, 1038-1041 (1988).
7. Carter, P. et al. High level Escherichia coli expression and production of a bivalent humanized antibody fragment. Bio/Technology 10, 163-167 (1992).
8. King, D.J. et al. Tumor localisation of engineered antibody fragments. Antibody Immunoconjugates and Radiopharmaceuticals 5, 159-170 (1992).
9. King, D.J. et al. Improved tumor targeting with chemically cross-linked recombinant antibody fragments. Cancer Res. 54, 6176-6185 (1994).
10. Monfardini, C. & Veronese, F.M. Stabilization of substances in circulation. Bioconjug. Chem 9, 418-450 (1998).
11. Kitamura, K. et al. Chemical engineering of the monoclonal antibody A7 by polyethylene glycol for targeting cancer chemotherapy. Cancer Res. 51, 4310-4315 (1991).
12. Pedley, R.B. et al. The potential for enhanced tumour localisation by poly(ethylene glycol) modification of anti-CEA antibody. Br. J. Cancer 70, 1126-1130 (1994).
13. Horn, U. et al. High volumetric yields of functional dimeric miniantibodies in Escherichia coli using an optimised expression vector and high cell density fermentation under non-limited growth conditions Appl. Microbiol. Biotechnol. 46, 524-532 (1996).
14. Zeitlin, L. et al. A humanized monoclonal antibody produced in transgenic plants for immunoprotection of the vagina against genital herpes Nat. Biotechnol. 16, 1361-1364 (1998).
15. Pen, J. in Transgenic plants: a production system for industrial and pharmaceutical proteins (eds Owens, M.R.L. & Pen, J.) 149-167 (John Wiley, New York; 1996).
16. 2 molecules made from Escherichia coli produced Fab' with hinge sequences conferring increased serum survival in an animal model. J. Immunol. Methods 217, 1-10 (1998).